[시장보고서]림프종 치료 시장 보고서 : 유형별, 검사 유형별, 약제별, 지역별(2025-2033년)

림프종 치료 시장 보고서 : 유형별, 검사 유형별, 약제별, 지역별(2025-2033년)

Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2025-2033

상품코드 : 1820085

리서치사 : IMARC

발행일 : 2025년 09월

페이지 정보 : 영문 146 Pages

라이선스 & 가격 (부가세 별도)

US $ 2,999

￦ 4,329,000

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 3,999

￦ 5,773,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999

￦ 7,217,000

PDF & Excel (Corporate License)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 림프종 치료 시장 규모는 2024년 143억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 274억 달러에 달하고, 2025년부터 2033년까지 7.13%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 치료 방법의 발전, 림프종 발병률 증가, 의료비 지출 급증, 지속적인 기술 혁신이 시장 성장을 주도하고 있습니다.

림프종 치료 시장 동향:

림프종 유병률 증가

호지킨림프종과 비호지킨림프종을 포함한 림프종 유병률은 인구 고령화와 진단 능력 향상 등의 요인으로 인해 전 세계적으로 증가하고 있습니다. 예를 들어, 미국암협회에 따르면 2024년에는 약 80,000명이 비호지킨림프종에 걸릴 것으로 예상하고 있습니다. 따라서 효율적인 치료에 대한 수요가 더욱 증가하여 향후 몇 년 동안 림프종 치료 시장의 원동력이 될 것으로 예측됩니다.

맞춤형 의료에 대한 관심 증가

맞춤형 의료에 대한 관심이 높아지면서 림프종 치료 시장의 성장에 큰 힘이 되고 있습니다. 예를 들어, IMARC에 따르면, 세계 정밀의료 시장 규모는 2023년 752억 달러에 달했습니다. 향후 IMARC Group은 2024년부터 2032년까지 9.1%의 연평균 성장률(CAGR)을 보이며 2032년까지 시장이 1,683억 달러에 달할 것으로 예측했습니다. 림프종 치료의 맞춤의료는 유전자, 분자, 면역학적 프로파일을 포함한 환자 개개인의 특성에 따라 치료법을 조정하는 것을 포함합니다. 이러한 요인들은 림프종 치료 시장 예측에 더욱 긍정적인 영향을 미칠 것입니다.

R&D 투자 증가

제약기업과 연구기관의 연구개발에 대한 막대한 투자는 림프종 치료제의 신규 개발 및 개선을 촉진하고, 혁신적인 치료법으로 시장을 확대하고 있습니다. 예를 들어, 2023년 11월, 혈액암 연구 민간 지원 기관인 Leukemia &Lymphoma Society(LLS)는 7개국 78개 연구팀에 6,500만 달러의 새로운 상금을 수여했습니다. 또한, 현재 진행 중인 임상시험 및 조사 연구는 치료법의 발전과 새로운 치료법 시장 도입에 기여하여 림프종 치료 시장의 수익을 증대시키고 있습니다.

시장 구조
주요 기업
주요 기업 개요
- Abbott Laboratories
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Merck & Co. Inc.
- Novartis International AG
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceutical Industries Ltd.

KSM

영문 목차

영문목차

The global lymphoma treatment market size reached USD 14.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The rising advancements in treatment modalities, increasing incidence of lymphoma, surging healthcare expenditure, and ongoing technological innovations are primarily driving the market's growth.

Lymphoma Treatment Market Trends:

Rising Prevalence of Lymphoma

The prevalence of lymphoma, including both Hodgkin and non-Hodgkin lymphoma, is rising globally due to factors like aging populations and improved diagnostic capabilities. For instance, according to the American Cancer Society, nearly 80,000 people will suffer from non-Hodgkin lymphoma in 2024. This further drives the demand for efficient treatment, further expected to propel the lymphoma treatment market in the coming years.

Surging Focus on Personalized Medicine

The rising focus on personalized medicine is significantly driving growth in the lymphoma treatment market. For instance, according to IMARC, the global precision medicine market size reached US$ 75.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 168.3 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032. Personalized medicine in lymphoma treatment involves tailoring therapies based on individual patient characteristics, including genetic, molecular, and immunological profiles. These factors further positively influence the lymphoma treatment market forecast.

Increasing R&D Investments

Significant investments in R&D by pharmaceutical companies and research institutions drive the development of new and improved lymphoma treatments, expanding the market with innovative therapies. For instance, in November 2023, the Leukemia & Lymphoma Society (LLS), a private supporter of blood cancer research, granted $65 million in new awards to 78 research teams in seven countries. Moreover, ongoing clinical trials and research studies contribute to the advancement of treatment options and the introduction of novel therapies to the market, thereby boosting the lymphoma treatment market revenue.

Global Lymphoma Treatment Industry Segmentation:

Breakup by Type:

Hodgkin Lymphoma
Non-Hodgkin Lymphoma

According to the lymphoma treatment market outlook, Hodgkin lymphoma comprises a smaller proportion of all lymphomas, accounting for approximately 10% of cases worldwide. Moreover, it is more prevalent in developed countries compared to developing regions. Moreover, non-Hodgkin lymphoma is more common than Hodgkin lymphoma, accounting for approximately 90% of all lymphoma cases globally. NHL incidence rates have been increasing over the past few decades.

Breakup by Test Type:

Chemotherapy
Radiation Therapy
Immunotherapy
Targeted Therapy
Biologic Therapy
Others

According to the lymphoma treatment market overview, chemotherapy involves the use of drugs to kill cancer cells or slow their growth. These drugs can be administered orally or intravenously and work by targeting rapidly dividing cells throughout the body. Moreover, radiation therapy uses high-energy beams to target and destroy cancer cells. It is often delivered externally (external beam radiation) or internally (brachytherapy). Apart from this, immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Key approaches include monoclonal antibodies and immune checkpoint inhibitors.

Breakup by Drug:

Adcetris
Rituxan
Opdivo
Imbruvica
Keytruda
Revlimid
Others

Adcetris is primarily used for the treatment of Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphoma (NHL), such as systemic anaplastic large cell lymphoma (sALCL). Moreover, Rituxan is a monoclonal antibody targeting CD20 antigen primarily used in B-cell NHL and certain autoimmune diseases like rheumatoid arthritis. Apart from this, Opdivo is an immune checkpoint inhibitor targeting PD-1 receptor used in various cancers, including melanoma, lung cancer, and Hodgkin lymphoma.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the lymphoma treatment market statistics, North America represents a significant portion of the global lymphoma treatment market owing to the higher prevalence of lymphoma, particularly non-Hodgkin lymphoma (NHL), due to factors like aging population and environmental exposures. Moreover, the increasing emphasis on genomic profiling and targeted therapies, is driving the market growth in Europe. Apart from this, the rising incidence of lymphoma in Asia Pacific, partly due to aging populations, urbanization, and changing lifestyles is supporting the industry's demand.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

Abbott Laboratories
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis International AG
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global lymphoma treatment market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the drug?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global lymphoma treatment market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Lymphoma Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Hodgkin Lymphoma
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Non-Hodgkin Lymphoma
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Test Type

7.1 Chemotherapy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Radiation Therapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Immunotherapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Targeted Therapy
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Biologic Therapy
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Drug

8.1 Adcetris
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Rituxan
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Opdivo
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Imbruvica
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Keytruda
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Revlimid
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
8.7 Others
- 8.7.1 Market Trends
- 8.7.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Bristol-Myers Squibb Company
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Eli Lilly and Company
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 F. Hoffmann-La Roche Ltd.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 SWOT Analysis
- 14.3.5 Johnson & Johnson Services, Inc.
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Merck & Co. Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Novartis International AG
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Spectrum Pharmaceuticals, Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Takeda Pharmaceutical Company Ltd.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Teva Pharmaceutical Industries Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis

한글목차

림프종 치료 시장 동향:

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 림프종 치료 시장

제6장 시장 내역 : 유형별

제7장 시장 내역 : 검사 유형별

제8장 시장 내역 : 약제별

제9장 시장 내역 : 지역별

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도